Update shared on 15 Nov 2025
Fair value Increased 9.29%Analysts have raised their price target for AbCellera Biologics from $9.33 to $10.20 per share, citing improved profit margin forecasts even though revenue growth expectations have slightly moderated.
What's in the News
- AbCellera Biologics has begun dosing the first participants in a Phase 1 clinical trial for ABCL575, an investigational antibody therapy aimed at treating moderate to severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions (Key Developments).
- ABCL575 targets OX40 ligand and is engineered for a dosing interval of once every six months, providing less frequent administration compared to current clinical-stage molecules (Key Developments).
- The Phase 1 study is a randomized, placebo-controlled, double-blind trial focused on assessing safety and tolerability in healthy participants after subcutaneous dosing of ABCL575. Study data is expected in mid 2026 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has increased from $9.33 to $10.20 per share, indicating a moderate upward adjustment in fair value estimates.
- Discount Rate has risen slightly from 6.97% to 7.58%, reflecting a minor change in risk or required return assumptions.
- Revenue Growth expectations have eased, with forecasts moving from 55.35% down to 53.87%.
- Net Profit Margin projections have improved from 14.21% to 15.70%, suggesting stronger anticipated profitability.
- Future P/E ratio has declined from 201.61x to 195.53x, which implies a marginally more attractive valuation based on forward earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.